NEW YORK (GenomeWeb) – Genomics plc, an Oxford, UK-based bioinformatics company, announced today that it has inked a deal with Biogen to screen drug targets for the firm.
Genomics will use its genomic data analysis and interpretation capabilities to refine Biogen’s drug target selection. The firm's platform combines proprietary algorithms and software with its integrated genome-phenome database and analytical expertise to uncover relationships between genetic variation and human health outcomes, it said.
"This agreement highlights the growing commitment within the pharmaceutical and biotech industries to systematically use human genetic data in research to increase the chance of success in drug development," Genomics CEO John Colenutt said in a statement.
Terms of the agreement were not disclosed.
Earlier this year, the firm inked a collaboration with Eisai's Integrated Human Genomics research unit, which focuses on developing therapies primarily for neurodegeneration, autoimmune diseases, and oncology.